As per the interim analysis from Phase 3 clinical trials, in over 28,000 volunteers, Zydus Cadila’s COVID vaccine has shown an efficacy rate of 66.6 per cent for symptomatic RT-PCR positive cases. Following the third dose of the vaccine, it was noted that no moderate case of COVID was seen in vaccine beneficiaries.
In addition, there were no severe illness or death reported in people who had received the second dose of the vaccine. However, the data from the phase three trial is not yet peer-reviewed.
With respect to the current development, the Chairman of the Zydus Group, Pankaj R Patel said, “We are extremely happy that our efforts to put out a safe, well-tolerated and efficacious vaccine to fight COVID-19 has become a reality with ZyCoV-D. To create the world’s first DNA vaccine at such a crucial juncture and despite all the challenges, is a tribute to the Indian research scientists and their spirit of innovation. I’d like to thank the Department of Biotechnology, Government of India for their support in this mission of Atma Nirbhar Bharat and Indian Vaccine Mission COVID Suraksha.”